Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 2

Status

Active not recruiting 4Recruiting 2

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 5NET 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 3Neuroendocrine Tumors 1Neoplasms 1Lung Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Bites and Stings 1

Interventions

Specimen Handling 641pembrolizumab 585Magnetic Resonance Spectroscopy 555Carboplatin 431Cyclophosphamide 381Cisplatin 379Biopsy 376Nivolumab 315Paclitaxel 314Gemcitabine 308Radiotherapy 286Bevacizumab 235Dexamethasone 218fludarabine 206Docetaxel 194durvalumab 189Oxaliplatin 189venetoclax 187Rituximab 175Fluorouracil 175atezolizumab 172Pemetrexed 167Capecitabine 164Radiosurgery 162Doxorubicin 162Radiation 160Ipilimumab 146Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
AMG 757 × 90 days × Clear all
NCT07005128 2026-05-22

DeLLphi-312

Amgen

Phase 3 Recruiting
330 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06117774 2026-04-29

DeLLphi-306

Amgen

Phase 3 Active not recruiting
404 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06502977 2026-04-15

DeLLphi-307

Amgen

Phase 2 Active not recruiting
32 enrolled 9 charts
EndocrineNET

Neoplasms, Neuroendocrine Tumors

NCT07037758 2026-03-27

DeLLphi-311

Amgen

Phase 1 Recruiting
380 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

NCT06745323 2026-03-03

DeLLphi-309

Amgen

Phase 2 Active not recruiting
252 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡